Related Interviews

Constructing Portfolios That Differ From the Index
May 31, 2019
DeGulis, John P.

The First Half of 2019 Expected to Be Rough for the Biotech Sector
March 15, 2019
Singh, Hartaj

Good Management Teams and Good Science are Creating Opportunities in Biotech
March 08, 2018
Singh, Hartaj

Biotech Space Lining Up for New Product Cycle
April 21, 2017
Singh, Hartaj

Opportunities in Regenerative Medicine, Cancer Immunotherapy Markets for Value Investors
July 06, 2015

Handpicked Stocks in Emerging Pharmaceuticals
November 24, 2014

Managing a Growth Portfolio with a Focus on Company-Specific Metrics
September 08, 2014

Seeking Growth at a Reasonable Price While Considering Secular Themes
May 02, 2014

Biotechnology Capital Inflows Reach Historic Highs
April 07, 2014

Increased Biotech Productivity and Innovation Reflected in FDA-Approved Drugs
August 23, 2013

Opportunities in Hepatitis C and Genomic Technologies
April 08, 2013

FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market
April 08, 2013

Hepatitis C Therapies Propel Growth in Biotech
August 30, 2012

"common Sense" Investment Management - Kendall J. Anderson - Anderson Griggs Portfolio Management
November 14, 2011

Defensive Plays In The Defense Space - Michael F. Ciarmoli - Keybanc Capital Markets Inc.
November 14, 2011

Investing In Small- & Midcap Biotech Companies - Dr. Jason Kantor - Rbc Capital Markets
April 04, 2011

Health Care Services & Tech Outlook - Ross Muken - Deutsche Bank Securities, Inc.
November 15, 2010

Overview Of Midwestern Regional Bank Metrics - Craig Siegenthaler - Credit Suisse
April 05, 2010

Update On Science Tools & Diagnostics - Isaac Ro - Leerink Swann & Company
January 25, 2010

Investing In Regulated Electric Utilities - Marc De Croisset - Macquarie Capital (usa) Inc.
May 18, 2009

Sector-focused Growth Management - Frank Mastrapasqua & Mauro M. Mastrapasqua - Mastrapasqua Asset Management
June 09, 2008

K.CRONK / T.LAPOINTE - COLUMBIA MANAGEMENT GROUP
June 27, 2005

KEVIN CAREY - 1ST SOURCE CORPORATION INVESTMENT ADVISORS INC
July 19, 2004

JONATHAN ROTHBERG - CURAGEN CORPORATION (CRGN)
March 08, 2004

L.holtz / Y.lipsker - Roger Engemann & Associates
July 28, 2003

Wayne Yetter - Synavant Inc (snvt)
September 13, 2002

Large Cap Biotechnology & Life Sciences: Ronald Renaud - Bear, Stearns & Co
September 13, 2002

Ian Smith - Vertex Pharmaceuticals Inc (vrtx)
June 02, 2002

R.schwarzkopf / S.gleason - Kayne Anderson Rudnick Investment Mgmt Llc
February 25, 2002

George Robson - Dendrite International (drte)
September 14, 2001

Japanese Semiconductor Companies & Electronics: Scott Foster - Lehman Brothers
September 12, 2001

Mary Ann Gray - Federated Kaufmann Fund
June 07, 2001

Mark Frevert - Enron Wholesale Services (ene)
May 31, 2001

Outlook For Biotechnology Stocks: William Slattery - Deerfield Management
December 18, 2000

D.altabef / D.katz - Matrix Asset Advisors
December 18, 2000

George Kellner - Kellner, Dileo & Co
November 20, 2000

Emerging Pharamaceutical Companies : Corey Davis - Chase H&q
January 13, 2000

Joe C. Cook Jr. - Amylin Pharmaceuticals (amln)
January 13, 2000

Ian Prosser - Bass Plc (bass.l)
January 03, 2000

Roundtable Forum: Major Chemicals
December 20, 1999

Biotherapeutics Stocks : Michael G. King Jr. - Robertson Stephens
December 06, 1999